HomeClinical TopicsFDA approves new combination treatment for acute myeloid leukemia

FDA approves new combination treatment for acute myeloid leukemia

On April 28, the U.S. Food and Drug Administration (FDA) approved Rydapt (midostaurin) for the treatment of adult patients with newly diagnosed acute myeloid leukemia who have the genetic mutation FLT3, in combination with chemotherapy. Read more

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Recent Content

For Nurse Practitioners

NP taking pregnant woman's blood pressure

AHA: It’s Safe to Treat High Blood Pressure During Pregnancy

High blood pressure during pregnancy can present significant risks to mother and child, but practitioners have sometimes be hesitant to prescribe blood pressure medication...